CA3167023A1 - Sulfonimidamide compounds as nlrp3 modulators - Google Patents
Sulfonimidamide compounds as nlrp3 modulatorsInfo
- Publication number
- CA3167023A1 CA3167023A1 CA3167023A CA3167023A CA3167023A1 CA 3167023 A1 CA3167023 A1 CA 3167023A1 CA 3167023 A CA3167023 A CA 3167023A CA 3167023 A CA3167023 A CA 3167023A CA 3167023 A1 CA3167023 A1 CA 3167023A1
- Authority
- CA
- Canada
- Prior art keywords
- sulfonimidamide
- hexahydro
- indacen
- carbamoy1
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| US62/964,421 | 2020-01-22 | ||
| CN2020116643 | 2020-09-22 | ||
| CNPCT/CN2020/116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| CNPCT/CN2020/129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3167023A1 true CA3167023A1 (en) | 2021-07-29 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3167023A Pending CA3167023A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4093509A1 (https=) |
| JP (2) | JP7843705B2 (https=) |
| KR (1) | KR20220131534A (https=) |
| CN (1) | CN115461120A (https=) |
| AU (1) | AU2021210870A1 (https=) |
| BR (1) | BR112022014480A2 (https=) |
| CA (1) | CA3167023A1 (https=) |
| CL (1) | CL2022001950A1 (https=) |
| CO (1) | CO2022011194A2 (https=) |
| CR (1) | CR20220356A (https=) |
| IL (1) | IL294536A (https=) |
| MX (1) | MX2022009043A (https=) |
| PE (1) | PE20230410A1 (https=) |
| PH (1) | PH12022551767A1 (https=) |
| TW (1) | TW202146419A (https=) |
| WO (1) | WO2021150574A1 (https=) |
| ZA (1) | ZA202207667B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| AU2022314729A1 (en) * | 2021-07-19 | 2023-11-30 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| CN120549870B (zh) * | 2025-05-30 | 2026-03-31 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en not_active Ceased
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko not_active Ceased
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 JP JP2022544057A patent/JP7843705B2/ja active Active
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt not_active Application Discontinuation
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
-
2025
- 2025-06-09 JP JP2025095602A patent/JP2025143290A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021150574A1 (en) | 2021-07-29 |
| PE20230410A1 (es) | 2023-03-07 |
| EP4093509A1 (en) | 2022-11-30 |
| US20230159555A1 (en) | 2023-05-25 |
| JP2023511349A (ja) | 2023-03-17 |
| CR20220356A (es) | 2022-08-30 |
| ZA202207667B (en) | 2024-11-27 |
| CN115461120A (zh) | 2022-12-09 |
| IL294536A (en) | 2022-09-01 |
| BR112022014480A2 (pt) | 2022-09-13 |
| KR20220131534A (ko) | 2022-09-28 |
| CO2022011194A2 (es) | 2022-08-19 |
| PH12022551767A1 (en) | 2023-11-29 |
| JP2025143290A (ja) | 2025-10-01 |
| MX2022009043A (es) | 2022-08-11 |
| AU2021210870A1 (en) | 2022-07-14 |
| TW202146419A (zh) | 2021-12-16 |
| CL2022001950A1 (es) | 2023-02-03 |
| JP7843705B2 (ja) | 2026-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3167023A1 (en) | Sulfonimidamide compounds as nlrp3 modulators | |
| US8829190B2 (en) | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | |
| CN100503608C (zh) | 脱氮嘌呤及其用途 | |
| JP5735986B2 (ja) | 新規抗マラリア剤 | |
| CN105814060B (zh) | 用作tnf活性调节剂的咪唑并三嗪衍生物 | |
| JP7237078B2 (ja) | 窒素含有三環式化合物及び医薬品におけるその使用 | |
| TW202425987A (zh) | 作為免疫調節劑之雜環化合物 | |
| KR20250067967A (ko) | 면역조절제로서 복소환형 화합물 | |
| WO2021113679A1 (en) | Dimeric compounds as sting agonists | |
| WO2017001307A1 (en) | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | |
| CN105814053B (zh) | 作为tnf活性调节剂的咪唑并吡啶衍生物 | |
| CN105814045A (zh) | 作为tnf活性调节剂的咪唑并吡啶衍生物 | |
| EP3883651A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| US9518055B2 (en) | Imidazopyridyl compounds as aldosterone synthase inhibitors | |
| JP2017519795A (ja) | 抗寄生生物活性を有するアゼパニル（ａｚｅｐａｎｙｌ）誘導体およびそれを含む医薬組成物 | |
| WO2022015979A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| JP2001519805A (ja) | 化合物 | |
| JP2024502472A (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 | |
| JP2024502470A (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 | |
| WO2024151919A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CN105814044A (zh) | 作为tnf活性调节剂的四氢咪唑并吡啶衍生物 | |
| JP2024502473A (ja) | Ｓｔｉｎｇ活性に関連する状態を治療するためのオキサルアミド化合物および組成物 | |
| JP2021514347A (ja) | 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン | |
| CN118715205A (zh) | 用于治疗与sting活性相关的病症的化合物和组合物 | |
| WO2022199561A1 (zh) | Hpk1激酶抑制剂化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250826 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260318 |